ICD-10 Code C81.90: Hodgkin Lymphoma, Unspecified — Complete Coding & Billing Guide

ICD-10-CM code C81.90 designates Hodgkin lymphoma, unspecified, unspecified site — a billable diagnosis code assigned when a provider has confirmed a Hodgkin lymphoma diagnosis but neither the histologic subtype nor the primary anatomic site of involvement is documented or determinable from available clinical information. This code sits within the C81 category (Hodgkin lymphoma) under Chapter 2 of the ICD-10-CM classification, covering malignant neoplasms of lymphoid, hematopoietic, and related tissue.

C81.90 is valid for HIPAA-covered transactions for fiscal year 2026 (October 1, 2025 – September 30, 2026), and has been a stable, unchanged code since ICD-10-CM was first implemented in fiscal year 2016.

What Does ICD-10 Code C81.90 Mean?

C81.90 is the least-specific billable code in the C81.9x family. It communicates two simultaneous layers of “unspecified”: the histologic subtype of Hodgkin lymphoma is not documented, and no primary site of lymph node involvement is identified. While unspecified codes are sometimes viewed as a coding shortcut, C81.90 has legitimate, compliant uses — most commonly during early workup when a diagnosis of Hodgkin’s disease has been established by biopsy but full staging and subtype classification are still pending.

Key attributes at a glance:

• Billable: Yes — valid for principal and secondary diagnosis positions
• Valid FY: 2026 (no changes from FY 2025)
• Applicable setting: Inpatient and outpatient
• MS-DRG assignment: MDC 17 — groups to DRGs 820–825 (with/without major procedures) and DRGs 840–842 (without procedures, based on MCC/CC status)
• CCSR default: Yes — default inpatient assignment for principal/first-listed diagnosis
• Chronic condition indicator: Yes — coded continuously while active treatment is ongoing

What Conditions and Diagnoses Does C81.90 Cover?

C81.90 applies when the provider has established a diagnosis of Hodgkin lymphoma — formerly called Hodgkin’s disease — but available documentation does not permit assignment of a more specific subtype or site code. Clinical scenarios where this code is appropriately used include:

• Biopsy-confirmed Hodgkin lymphoma with Reed-Sternberg cells identified but histologic classification not yet finalized by pathology
• Cases where the treating provider documents “Hodgkin lymphoma” without specifying classical versus nodular lymphocyte-predominant subtype
• Encounters occurring between initial diagnosis and completion of full staging workup (e.g., PET-CT or bone marrow biopsy not yet resulted)
• Chart documentation that references “Hodgkin’s disease” without site specification — a recognized clinical synonym

What Does C81.90 Specifically Exclude?

The Excludes1 note at the C81 category level prohibits use of any C81.xx code when the clinical scenario reflects:

• Personal history of Hodgkin lymphoma — use Z85.71 instead when the disease is no longer active and treatment has been completed
• C81.90 should not be used when remission is explicitly documented — use C81.9A (Hodgkin lymphoma, unspecified, in remission) for that scenario

When Is C81.90 the Right Code to Use?

The most common coder error in the C81 family is defaulting to C81.90 when a more specific code is supportable by the medical record. Use C81.90 only after completing this decision sequence:

1. Confirm the diagnosis is Hodgkin lymphoma — distinguish from Non-Hodgkin lymphoma (C82–C86 range) and other lymphoproliferative disorders.
2. Review the pathology report — if a histologic subtype (nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted, nodular lymphocyte-predominant) is identified, assign the corresponding specific C81.1x–C81.4x or C81.0x code.
3. Review imaging and staging documentation — if a primary nodal site is identified, move to the site-specific subcode (C81.91–C81.98).
4. Check whether remission or personal history language is used — if so, do not assign C81.90.
5. Assign C81.90 only when both subtype and site remain genuinely undocumentable from the encounter-specific record.

In practice, coders frequently encounter C81.90 on initial diagnostic encounters, hospital admissions for staging workup, and the first chemotherapy visit before the full hematopathology report is available. Once that report returns, the claim for subsequent encounters should be updated to the most specific code available.

How Does C81.90 Differ From C81.91 and Other Site-Specific Subcodes?

The sixth character in the C81.9x series identifies the primary site of lymph node involvement. C81.90 and its sibling codes differ only in that dimension — not in histologic subtype.

Code	Description	When to Use
C81.90	Hodgkin lymphoma, unspecified — unspecified site	No subtype; no site documented
C81.91	Hodgkin lymphoma, unspecified — lymph nodes of head, face, and neck	Cervical/supraclavicular involvement documented
C81.92	Hodgkin lymphoma, unspecified — intrathoracic lymph nodes	Mediastinal involvement documented
C81.93	Hodgkin lymphoma, unspecified — intra-abdominal lymph nodes	Abdominal nodal involvement documented
C81.9A	Hodgkin lymphoma, unspecified — in remission	Active treatment completed; remission documented
C81.1x	Nodular sclerosis Hodgkin lymphoma (with site 6th character)	Subtype documented in pathology report

What Documentation Is Required to Support C81.90?

The medical billing documentation requirements for C81.90 center on demonstrating that the diagnosis of Hodgkin lymphoma is established AND that the specificity gap — no subtype, no site — is genuinely a reflection of available clinical information rather than a documentation deficiency.

What Must the Provider Document in the Clinical Notes?

1. Explicit diagnosis statement — the provider must document “Hodgkin lymphoma” or an accepted synonym (e.g., “Hodgkin’s disease,” “lymphoma, Hodgkin type”) in the assessment, impression, or problem list.
2. Basis for diagnosis — the clinical note should reference that the diagnosis has been established (typically via biopsy), even if results are still pending completion.
3. Absence of subtype specification — ideally, the note reflects that “subtype to be determined pending final pathology” or similar language confirming specificity is not yet available.
4. Active vs. remission status — documentation must indicate the disease is currently active (not in remission, not a personal history) to justify C81.90 over Z85.71 or C81.9A.

Which Diagnostic or Lab Results Support This Code?

• Tissue biopsy results confirming lymphoma with Reed-Sternberg cells (even if formal subtyping is pending)
• Excisional or core needle biopsy pathology reports from lymph node tissue
• Immunohistochemistry (IHC) panel showing CD30 positivity (characteristic of classical Hodgkin lymphoma) without full subtype classification
• Bone marrow biopsy documentation, even if results reflect “involvement pending characterization”
• PET-CT or CT staging reports that identify lymphadenopathy without site-specific nodal mapping completed

What Is the Documentation Standard for Inpatient vs. Outpatient Settings?

Setting	Documentation Standard	Coding Note
Inpatient	Code the confirmed diagnosis — “suspected” not required; working diagnosis sufficient	C81.90 appropriate even if staging not complete at discharge
Outpatient	Code only confirmed diagnoses — do not code “rule out” or “possible” Hodgkin lymphoma	Must have explicit provider diagnosis statement to assign C81.90
Physician office	Confirmed diagnosis required; pathology report in chart supports code	If subtype on report, update to specific code immediately

How Does C81.90 Affect Medical Billing and Claims?

C81.90 is a malignant neoplasm code, which carries significant downstream billing implications. Payers treat active Hodgkin lymphoma claims differently than non-malignant conditions in several ways:

• Medical necessity baseline is established by the malignancy itself — C81.90 is generally sufficient to support oncologic chemotherapy, radiation planning, and associated evaluation and management services
• DRG impact — inpatient claims with C81.90 as the principal diagnosis will map to MDC 17; the specific DRG assignment (820–842) depends on whether major OR procedures are performed and the presence of MCC or CC complications
• Continuous active coding — Hodgkin lymphoma should be coded on every encounter while the patient is actively receiving treatment, including chemotherapy, radiation therapy, and monitoring visits
• Do not omit on subsequent encounters — a common billing gap occurs when coders drop the lymphoma code after the initial diagnosis visit, incorrectly treating it as resolved

What CPT or Procedure Codes Are Commonly Billed With C81.90?

CPT Code	Description	Typical Pairing Context
96413	Chemotherapy administration, IV infusion, first hour	First-line ABVD/BV-AVD regimens
96415	Chemotherapy administration, IV infusion, each additional hour	Extended infusion sessions
77261–77263	Radiation treatment planning (simple/intermediate/complex)	Involved-site radiation therapy
38505	Biopsy or excision of lymph node, needle core	Diagnostic biopsy at initial staging
38570	Laparoscopic lymph node biopsy	Staging biopsy, intra-abdominal nodes
78816	PET imaging, skull base to mid-thigh	Staging and treatment response imaging
99213–99215	Office/outpatient E&M	Oncology follow-up visits

Are There Any Prior Authorization or Coverage Restrictions?

• Chemotherapy regimens (particularly brentuximab vedotin-containing regimens) commonly require prior authorization from commercial payers; C81.90 alone may trigger requests for more specific staging documentation before authorization is approved
• Medicare — no National Coverage Determination (NCD) specifically restricts C81.90, but Local Coverage Determinations (LCDs) for chemotherapy drugs and PET imaging often require stage documentation as a supporting criterion
• Radiation therapy planning typically requires a documented diagnosis of active malignancy — C81.90 satisfies this requirement
• Some payers may request the pathology report or staging documentation to confirm medical necessity when an unspecified code is submitted for high-cost interventions

What Coding Errors Should You Avoid With C81.90?

In practice, auditors consistently flag the following errors in Hodgkin lymphoma coding:

1. Using C81.90 when a specific subtype is documented — if the pathology report identifies nodular sclerosis, mixed cellularity, or any other subtype, C81.1x–C81.4x is required; defaulting to C81.90 constitutes under-coding.
2. Using C81.90 when a site is documented — any biopsy or imaging report identifying a primary nodal site (e.g., cervical, mediastinal) obligates the coder to assign C81.91–C81.98.
3. Coding C81.90 instead of C81.9A for patients in remission — when the provider documents “remission,” C81.9A is required; C81.90 implies active disease.
4. Coding C81.90 after disease is cured/in complete remission — use Z85.71 (personal history of Hodgkin lymphoma) when treatment is complete and the patient is no longer under active treatment.
5. Omitting C81.90 on chemotherapy encounter claims — some coders incorrectly list only the Z51.11 (encounter for antineoplastic chemotherapy) without the underlying malignancy code, which fails medical necessity requirements.
6. Submitting with the decimal point electronically — electronic claim formats require C8190 (no decimal); some clearinghouses strip it, but submitting C81.90 with the decimal risks rejection at certain clearinghouses.

What Do Auditors Look for When Reviewing Claims With C81.90?

• Pathology report in the chart — auditors will pull the biopsy report to verify that subtype truly was not specified, and will expect to see a more specific code on later encounters once results are finalized
• Pattern of repeated C81.90 claims — if a facility consistently bills C81.90 across multiple encounters for the same patient when pathology has long since returned, this signals a systemic coding failure
• Remission documentation — auditors check whether provider notes contain language like “in remission,” “complete response,” or “end of treatment” and whether the coding reflects that change
• DRG optimization patterns — inpatient coders should document and code all CCs/MCCs accurately; under- or over-coding complications alongside C81.90 is a frequent audit target

How Does C81.90 Relate to Other ICD-10 Codes?

Understanding C81.90’s position within the broader ICD-10-CM Official Coding Guidelines requires knowing which codes it interacts with most frequently.

Related Code	Relationship Type	Key Distinction
C81.91–C81.98	Same subtype, site-specific variants	Use when primary nodal site is documented
C81.9A	Remission variant of C81.9x	Use when provider explicitly documents remission
C81.10–C81.19	More specific — nodular sclerosis subtype	Use when pathology confirms NS histology
C81.20–C81.29	More specific — mixed cellularity subtype	Use when pathology confirms MC histology
C82–C86	Non-Hodgkin lymphoma codes	Mutually exclusive — distinct disease entities
C85.90	Non-Hodgkin lymphoma, unspecified	Do not confuse with C81.90; Reed-Sternberg cells distinguish HL from NHL
Z85.71	Personal history of Hodgkin lymphoma	Use when disease is resolved and treatment complete
Z51.11	Encounter for antineoplastic chemotherapy	Secondary code; C81.90 sequences first as the primary malignancy
Z51.12	Encounter for antineoplastic immunotherapy	Secondary code in same sequencing pattern

What Is the Correct Code Sequencing When C81.90 Appears With Other Diagnoses?

1. C81.90 sequences as the principal/first-listed diagnosis when the reason for the encounter is evaluation, staging, or treatment of the lymphoma itself.
2. Z51.11 or Z51.12 sequences first only when the encounter is solely for chemotherapy or immunotherapy administration — per ICD-10-CM Official Coding Guidelines Section I.C.2.e — with C81.90 then coded as an additional diagnosis.
3. Complication codes (e.g., nausea from chemotherapy, neutropenia) are coded as additional diagnoses after C81.90 in non-chemotherapy-only encounters.
4. Anemia in neoplastic disease — assign D63.0 as an additional code when the provider documents anemia due to the malignancy; this code follows C81.90 and carries significant CC weight for DRG assignment.

Real-World Coding Scenario — How C81.90 Is Applied in Practice

Patient encounter: A 26-year-old male presents to the hematology/oncology clinic following a recent excisional lymph node biopsy at an outside facility. The referring physician has documented “Hodgkin lymphoma confirmed by biopsy” in the referral note. The full pathology report from the outside facility has not yet been received. The oncologist documents the working diagnosis as “Hodgkin lymphoma” and orders PET-CT staging. The encounter purpose is new patient evaluation and treatment planning.

Correct Code Application

• C81.90 — Hodgkin lymphoma, unspecified, unspecified site: Rationale: Diagnosis is confirmed by biopsy per referral documentation; histologic subtype not yet available; no site specified in available records; disease is active.
• 99205 (or appropriate new patient E&M level) — New patient office visit for oncology evaluation
• No chemotherapy code is appropriate — no treatment administered this encounter

Common Mistake in This Scenario

• Incorrect code assigned: C81.10 (Nodular sclerosis Hodgkin lymphoma, unspecified site)
• Why it fails: The subtype has not been documented by any provider with access to pathology findings. Assigning a specific subtype code without supporting pathology documentation constitutes up-coding and creates an audit risk if the final pathology report later identifies a different subtype (e.g., mixed cellularity).
• Correct action: Once the pathology report is received and reviewed at the follow-up visit, update to the most specific code (e.g., C81.11 if nodular sclerosis involving cervical nodes is confirmed).

Frequently Asked Questions About ICD-10 Code C81.90

Is ICD-10 Code C81.90 Still Valid for FY 2026?

C81.90 remains a valid, billable ICD-10-CM code for fiscal year 2026 with no changes to its description, validity, or instructional notes from the prior fiscal year. The code has been stable and unchanged since ICD-10-CM was first implemented in FY 2016. Coders should verify the current year’s code set annually using the ICD-10-CM Official Coding Guidelines released by CMS each October.

When Should I Use C81.90 Instead of a Specific C81 Subtype Code?

C81.90 is appropriate only when the histologic subtype of Hodgkin lymphoma is genuinely not documented or determinable from available records for that encounter. If any pathology report in the medical record identifies a subtype (nodular sclerosis, mixed cellularity, etc.), the corresponding specific code must be assigned — C81.90 becomes incorrect once specificity is available.

What Is the Difference Between C81.90 and C81.9A?

C81.90 designates active, unspecified Hodgkin lymphoma with no documented site, while C81.9A designates the same histologic scenario but in documented remission. The key determinant is the provider’s explicit language: if the note contains terms like “in remission,” “complete response,” or “end of treatment surveillance,” C81.9A applies. Never assign C81.90 to a remission encounter.

Can C81.90 Be Used on a Claim With Chemotherapy CPT Codes?

Yes, C81.90 can and should appear on claims for chemotherapy encounters. Per ICD-10-CM sequencing guidelines, when the sole purpose of the encounter is chemotherapy administration, Z51.11 sequences as the first-listed code with C81.90 as the secondary diagnosis. When the encounter includes evaluation and management in addition to treatment, C81.90 typically sequences first.

What Is the Difference Between C81.90 and C85.90?

C81.90 designates Hodgkin lymphoma — a specific cancer of the lymphatic system characterized by the presence of Reed-Sternberg cells. C85.90 designates Non-Hodgkin lymphoma, unspecified, which covers a broad and distinct group of lymphoid malignancies without Reed-Sternberg cell morphology. These two codes are never interchangeable and represent clinically and histologically separate disease categories.

Does C81.90 Require a Specific Stage to Be Coded Alongside It?

No separate ICD-10-CM code exists for Hodgkin lymphoma staging (Ann Arbor Stage I–IV). Stage is not captured in the diagnosis code itself under ICD-10-CM. However, for purposes of medical necessity and prior authorization, particularly for PET-CT imaging and advanced drug regimens, payers often require staging documentation in the clinical notes even though it is not a coding requirement per se.

Key Takeaways

Everything a coder or biller needs to remember about C81.90:

• C81.90 is a legitimate but last-resort code — always verify that no subtype and no site information is available before assigning it
• Once pathology returns with a subtype classification, update to the specific code on all subsequent encounters
• Remission ≠ C81.90 — use C81.9A when remission is documented; use Z85.71 when treatment is fully complete
• On chemotherapy-only encounters, Z51.11 sequences first and C81.90 codes as additional diagnosis
• Electronic claims must omit the decimal — submit as C8190, not C81.90
• C81.90 groups to MDC 17 DRGs; accurate coding of complications (anemia, neutropenia) has meaningful impact on DRG weight and reimbursement
• Auditors will compare your coding pattern against available pathology documentation — ensure your chart supports the “unspecified” designation at the time of each encounter

For official guidance, review the ICD-10-CM Official Coding Guidelines published annually by CMS, and consult AHA Coding Clinic for lymphoma-specific coding advisories.